Enhancing therapeutic efficacy through designed aggregation of nanoparticles

Biomaterials

Volumn 35, Issue 27, 2014, Pages 7860-7869

  Sadhukha, Tanmoy ^a   Wiedmann, Timothy S ^a   Panyam, Jayanth ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aggregation; Apoptosis; Autophagy; Magnetic hyperthermia; Necrosis; Superparamagnetic iron oxide

Indexed keywords

AGGLOMERATION; AGGREGATES; CELL DEATH; IRON OXIDES; NANOPARTICLES; PARTICLE SIZE; SUPERPARAMAGNETISM;

ANTI-CANCER THERAPEUTICS; AUTOPHAGY; BIOLOGICAL ENVIRONMENTS; BIOLOGICAL PERFORMANCE; INORGANIC NANOPARTICLE; MAGNETIC HYPERTHERMIA; NECROSIS; SUPERPARAMAGNETIC IRON OXIDES;

NANOMAGNETICS;

LACTATE DEHYDROGENASE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; DEXTRAN; MAGNETITE NANOPARTICLE; NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; ENZYME RELEASE; EXPERIMENTAL HYPERTHERMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; MAGNETIC HYPERTHERMIA; MEMBRANE DAMAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; THERAPY EFFECT; TUMOR CELL; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL MEMBRANE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; LUNG TUMOR; MAGNETISM; NUDE MOUSE; PATHOLOGY; TOXICITY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; DEXTRANS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC PHENOMENA; MAGNETITE NANOPARTICLES; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; PARTICLE SIZE;

EID: 84903488238     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.085     Document Type: Article

References (53)

1. Matsumura Y., Maeda H. Anew concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt 1):6387-6392.
2. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006, 12(4):1317-1324.
3. Singh S., Sharma A., Robertson G.P. Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res 2012, 72(22):5663-5668.
4. Perrault S.D., Walkey C., Jennings T., Fischer H.C., Chan W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 2009, 9(5):1909-1915.
5. Kong G., Braun R.D., Dewhirst M.W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 2000, 60(16):4440-4445.
6. Qian X., Peng X.H., Ansari D.O., Yin-Goen Q., Chen G.Z., Shin D.M., et al. Invivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol 2008, 26(1):83-90.
7. Lee H., Lee E., Kim do K., Jang N.K., Jeong Y.Y., Jon S. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for invivo cancer imaging. JAm Chem Soc 2006, 128(22):7383-7389.
8. Peng X.H., Qian X., Mao H., Wang A.Y., Chen Z.G., Nie S., et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomed 2008, 3(3):311-321.
9. Diaz B., Sanchez-Espinel C., Arruebo M., Faro J., de Miguel E., Magadan S., et al. Assessing methods for blood cell cytotoxic responses to inorganic nanoparticles and nanoparticle aggregates. Small 2008, 4(11):2025-2034.
10. van Landeghem F.K., Maier-Hauff K., Jordan A., Hoffmann K.T., Gneveckow U., Scholz R., et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials 2009, 30(1):52-57.
11. Safi M., Sarrouj H., Sandre O., Mignet N., Berret J.F. Interactions between sub-10-nm iron and cerium oxide nanoparticles and 3T3 fibroblasts: the role of the coating and aggregation state. Nanotechnology 2010, 21(14):145103.
12. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A 2008, 105(38):14265-14270.
13. Hiergeist R., Andrä W., Buske N., Hergt R., Hilger I., Richter U., et al. Application of magnetite ferrofluids for hyperthermia. JMagn Magn Mater 1999, 201(1-3):420-422.
14. Jordan A., Scholz R., Wust P., Fähling H., Roland F. Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. JMagn Magn Mater 1999, 201(1-3):413-419.
15. Hergt R., Andra W., d'Ambly C.G., Hilger I., Kaiser W.A., Richter U., et al. Physical limits of hyperthermia using magnetite fine particles. IEEE Trans Magn 1998, 34(5):3745-3754.
16. Rosensweig R.E. Heating magnetic fluid with alternating magnetic field. JMagn Magn Mater 2002, 252(0):370-374.
17. Tasci T.O., Vargel I., Arat A., Guzel E., Korkusuz P., Atalar E. Focused RF hyperthermia using magnetic fluids. Med Phys 2009, 36(5):1906-1912.
18. Tseng H.Y., Lee G.B., Lee C.Y., Shih Y.H., Lin X.Z. Localised heating of tumours utilising injectable magnetic nanoparticles for hyperthermia cancer therapy. IET Nanobiotechnol 2009, 3(2):46-54.
19. Foy S.P., Manthe R.L., Foy S.T., Dimitrijevic S., Krishnamurthy N., Labhasetwar V. Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. ACS Nano 2010, 4(9):5217-5224.
20. Krishna Murti G.S.R., Moharir A.V., Sarma V.A.K. Spectrophotometric determination of iron with orthophenanthroline. Microchem J 1970, 15(4):585-589.
21. Giustini A.J., Ivkov R., Hoopes P.J. Magnetic nanoparticle biodistribution following intratumoral administration. Nanotechnology 2011, 22(34):345101.
22. Luchetti F., Canonico B., Della Felice M., Burattini S., Battistelli M., Papa S., et al. Hyperthermia triggers apoptosis and affects cell adhesiveness in human neuroblastoma cells. Histol Histopathol 2003, 18(4):1041-1052.
23. Rodriguez-Luccioni H.L., Latorre-Esteves M., Mendez-Vega J., Soto O., Rodriguez A.R., Rinaldi C., et al. Enhanced reduction in cell viability by hyperthermia induced by magnetic nanoparticles. Int J Nanomed 2011, 6:373-380.
24. Takasu T., Lyons J.C., Park H.J., Song C.W. Apoptosis and perturbation of cell cycle progression in an acidic environment after hyperthermia. Cancer Res 1998, 58(12):2504-2508.
25. Lazebnik Y.A., Kaufmann S.H., Desnoyers S., Poirier G.G., Earnshaw W.C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994, 371(6495):346-347.
26. Uchiyama Y. Autophagic cell death and its execution by lysosomal cathepsins. Arch Histol Cytol 2001, 64(3):233-246.
27. Chaitanya G.V., Steven A.J., Babu P.P. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 2010, 8:31.
28. Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000, 19(21):5720-5728.
29. Tsujimoto Y., Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ 2005, 12(Suppl.2):1528-1534.
30. Zhang H., Kong X., Kang J., Su J., Li Y., Zhong J., et al. Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci 2009, 110(2):376-388.
31. Chen Y., McMillan-Ward E., Kong J., Israels S.J., Gibson S.B. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ 2008, 15(1):171-182.
32. Cerella C., D'Alessio M., Cristofanon S., De Nicola M., Radogna F., Dicato M., et al. Subapoptogenic oxidative stress strongly increases the activity of the glycolytic key enzyme glyceraldehyde 3-phosphate dehydrogenase. Ann N Y Acad Sci 2009, 1171:583-590.
33. Colell A., Ricci J.E., Tait S., Milasta S., Maurer U., Bouchier-Hayes L., et al. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 2007, 129(5):983-997.
34. Proskuryakov S.Y., Konoplyannikov A.G., Gabai V.L. Necrosis: a specific form of programmed cell death?. Exp Cell Res 2003, 283(1):1-16.
35. Liu D., Wang L., Wang Z., Cuschieri A. Magnetoporation and magnetolysis of cancer cells via carbon nanotubes induced by rotating magnetic fields. Nano Lett 2012, 12(10):5117-5121.
36. Frossard J.L. Heat shock protein 70 (HSP70) prolongs survival in rats exposed to hyperthermia. Eur J Clin Invest 1999, 29(6):561-562.
37. Ito A., Shinkai M., Honda H., Yoshikawa K., Saga S., Wakabayashi T., et al. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 2003, 52(2):80-88.
38. Patil Y., Sadhukha T., Ma L., Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. JControl Release 2009, 136(1):21-29.
39. Barros L.F., Kanaseki T., Sabirov R., Morishima S., Castro J., Bittner C.X., et al. Apoptotic and necrotic blebs in epithelial cells display similar neck diameters but different kinase dependency. Cell Death Differ 2003, 10(6):687-697.
40. Huang H., Delikanli S., Zeng H., Ferkey D.M., Pralle A. Remote control of ion channels and neurons through magnetic-field heating of nanoparticles. Nat Nanotechnol 2010, 5(8):602-606.
41. Polo-Corrales L., Rinaldi C. Monitoring iron oxide nanoparticle surface temperature in an alternating magnetic field using thermoresponsive fluorescent polymers. JAppl Phys 2012, 111(7):07B334. 3.
42. Gravante G., Sconocchia G., Ong S.L., Dennison A.R., Lloyd D.M. Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies. Liver Int 2009, 29(1):18-24.
43. Mroz P., Hashmi J.T., Huang Y.-Y., Lange N., Hamblin M.R. Stimulation of anti-tumor immunity by photodynamic therapy. Exp Rev Clin Immunol 2010, 7(1):75-91.
44. Takehara T., Uemura A., Tatsumi T., Suzuki T., Kimura R., Shiotani A., et al. Natural killer cell-mediated ablation of metastatic liver tumors by hydrodynamic injection of IFNα gene to mice. Int J Cancer 2007, 120(6):1252-1260.
45. Carrstensen H., Muller R.H., Muller B.W. Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake. Clin Nutr 1992, 11(5):289-297.
46. Mansour H.M., Rhee Y.S., Wu X. Nanomedicine in pulmonary delivery. Int J Nanomed 2009, 4:299-319.
47. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007, 6(1):67-74.
48. Lennon F.E., Mirzapoiazova T., Mambetsariev B., Salgia R., Moss J., Singleton P.A. Overexpression of the mu-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology 2012, 116(4):857-867.
49. Zarogoulidis P., Chatzaki E., Porpodis K., Domvri K., Hohenforst-Schmidt W., Goldberg E.P., et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomed 2012, 7:1551-1572.
50. Yi D., Wiedmann T.S. Inhalation adjuvant therapy for lung cancer. JAerosol Med Pulm Drug Deliv 2010, 23(4):181-187.
51. Bomers J.G.R., Sedelaar J.P.M., Barentsz J.O., Fütterer J.J. MRI-guided interventions for the treatment of prostate cancer. Am J Roentgenol 2012, 199(4):714-720.
52. Cornelis F., Balageas P., Le Bras Y., Rigou G., Boutault J.R., Bouzgarrou M., et al. Radiologically-guided thermal ablation of renal tumours. Diagn Interv Radiol 2012, 93(4):246-261.
53. Sharma A., Abtin F., Shepard J.-A.O. Image-guided ablative therapies for lung cancer. Radiol Clin North Am 2012, 50(5):975-999.